Gennex Laboratories Share Price

Gennex Laboratories Investment Rating

• Master Rating:

• Gennex Laboratories has an operating revenue of Rs. 61.21 Cr. on a trailing 12-month basis. An annual revenue growth of 4% is not great, Pre-tax margin of 8% is okay, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 56 which is a POOR score indicating inconsistency in earnings, a RS Rating of 26 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 105 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of E is the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.